Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC 0148-0000-0362 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Part 1, level 1-7 escalating doses | EXPERIMENTAL | - |
| Part 2, cross-over | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NNC 0148-0000-0362 | DRUG | Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group |
| insulin glargine | DRUG | As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group |
| placebo | DRUG | Subjects will receive a single dose of oral placebo within each dose group |
Inclusion Criteria: * Body mass index 18-28 kg/m\^2 (both inclusive) * Subject who is considered to be healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
NNC 0148-0000-0362 is an investigational small molecule being developed for the treatment of diabetes, including type 2 diabetes. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
NNC 0148-0000-0362 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO.
NNC 0148-0000-0362 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. One Phase 1 trial has been completed.
NNC 0148-0000-0362 has been studied in one completed Phase 1 trial, NCT01597713, which investigated its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. The trial enrolled 83 participants and was conducted in Germany.
NNC 0148-0000-0362 is the same compound as NNC0148-0000-0362, with the hyphenation being a formatting variation. Both names refer to the same investigational drug developed by Novo Nordisk.